3 days ago
Lots of investors keep coming back to dividend stocks for a pretty simple reason: While the market is often busy chasing whatever happens to be hot that week, a growing dividend is something a company actually has to earn. It has to generate the cash to keep paying investors quarter after quarter, year after year.
That makes dividends especially appealing when the market and the economy feel like they're being pulled in every direction. A company can dress up a press release, but it can't fake the cash sitting in its bank account. When it comes time to pay a dividend, the money is either there or it isn't.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ****** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
What interests me most, though, aren't necessarily the big, well-known dividend payers. I'm more interested in the companies flying under the radar that have increased their payouts for decades while also making meaningful changes to their underlying businesses today. These four companies fit that description.
Universal (NYSE: UVV) is the highest yielder here, paying out around 7.4% at recent prices, and it has raised its dividend for 56 consecutive years. This raise makes it a Dividend King, a company that has delivered 50 or more years of annual dividend increases. Universal isn't a cigarette maker, but it is the world's largest leaf tobacco exporter and importer. It supplies tobacco companies rather than selling to smokers directly, which is why it rarely shows up in articles about tobacco stocks.
#market
That makes dividends especially appealing when the market and the economy feel like they're being pulled in every direction. A company can dress up a press release, but it can't fake the cash sitting in its bank account. When it comes time to pay a dividend, the money is either there or it isn't.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ****** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
What interests me most, though, aren't necessarily the big, well-known dividend payers. I'm more interested in the companies flying under the radar that have increased their payouts for decades while also making meaningful changes to their underlying businesses today. These four companies fit that description.
Universal (NYSE: UVV) is the highest yielder here, paying out around 7.4% at recent prices, and it has raised its dividend for 56 consecutive years. This raise makes it a Dividend King, a company that has delivered 50 or more years of annual dividend increases. Universal isn't a cigarette maker, but it is the world's largest leaf tobacco exporter and importer. It supplies tobacco companies rather than selling to smokers directly, which is why it rarely shows up in articles about tobacco stocks.
#market
21 days ago
On August 6, James Hardie Industries (NYSE:JHX) reported results for the quarter ended June 30 and beat its own numbers by enough to raise guidance just three months into the fiscal year. Net sales jumped 64% year over year to $1.475 billion, adjusted EBITDA climbed 79% to $422.1 million, and both figures came in ahead of what management had originally guided investors to expect. For a company that closed a transformative acquisition less than a year earlier, that kind of overshoot forces a reassessment of the growth story ahead.
The headline growth number is inflated by the AZEK Exteriors deal folded into the base, so the more telling figure is the 12% pro forma net sales growth, which also beat original guidance. Siding & Trim, the core fiber cement business, posted organic net sales growth of 20% as North American fiber cement volumes returned to growth for the first time in several quarters. CEO Aaron Erter tied that to share gains against vinyl and other competing materials, along with programs like ColorPlus and Expanded Statement drawing more of the higher-end repair and remodel market. Adjusted EBITDA margin in that segment expanded 140 basis points to 33.5%, powered by favorable pricing, cheaper raw materials, and continued savings from the company's Hardie Manufacturing Operating System even as freight costs rose.
Management also said cost synergies from the AZEK integration are running ahead of schedule and revenue synergies are on track, evidenced by newly expanded nationwide distribution partnerships with Boise Cascade and other regional distributors. In Deck, Rail & Accessories, sell-through accelerated every month of the quarter and outpaced shipments, pulling channel inventory back to normal levels and setting up a cleaner back half of the year. Free cash flow more than doubled to $254.2 million, and the company used the cash to pay down $400 million of senior unsecured notes.
Erter was careful to frame the beat as execution rather than a healthier market, telling investors the company is "not ***** uming a housing market improvement" for the rest of fiscal 2027. Part of the quarter's strength came from an easy comparison, since channel inventory was deliberately reduced a year earlier, and management said that benefit is expected to moderate as the year goes on. Deck, Rail & Accessories net sales actually fell 5% on a pro forma basis because the company intentionally cut production to work down channel inventory, leaving the segment with an operating loss of $3.3 million for the quarter.
#Growth #sales #management
The headline growth number is inflated by the AZEK Exteriors deal folded into the base, so the more telling figure is the 12% pro forma net sales growth, which also beat original guidance. Siding & Trim, the core fiber cement business, posted organic net sales growth of 20% as North American fiber cement volumes returned to growth for the first time in several quarters. CEO Aaron Erter tied that to share gains against vinyl and other competing materials, along with programs like ColorPlus and Expanded Statement drawing more of the higher-end repair and remodel market. Adjusted EBITDA margin in that segment expanded 140 basis points to 33.5%, powered by favorable pricing, cheaper raw materials, and continued savings from the company's Hardie Manufacturing Operating System even as freight costs rose.
Management also said cost synergies from the AZEK integration are running ahead of schedule and revenue synergies are on track, evidenced by newly expanded nationwide distribution partnerships with Boise Cascade and other regional distributors. In Deck, Rail & Accessories, sell-through accelerated every month of the quarter and outpaced shipments, pulling channel inventory back to normal levels and setting up a cleaner back half of the year. Free cash flow more than doubled to $254.2 million, and the company used the cash to pay down $400 million of senior unsecured notes.
Erter was careful to frame the beat as execution rather than a healthier market, telling investors the company is "not ***** uming a housing market improvement" for the rest of fiscal 2027. Part of the quarter's strength came from an easy comparison, since channel inventory was deliberately reduced a year earlier, and management said that benefit is expected to moderate as the year goes on. Deck, Rail & Accessories net sales actually fell 5% on a pro forma basis because the company intentionally cut production to work down channel inventory, leaving the segment with an operating loss of $3.3 million for the quarter.
#Growth #sales #management
23 days ago
Eli Lilly (NYSE: LLY) has been on a historic run over the past five years, outperforming similarly sized peers in the pharmaceutical industry and becoming the first healthcare stock to reach a $1 trillion market cap. The company's diabetes and weight-loss portfolio has been the main engine behind its terrific performance of late, and it remains strong. During the second quarter, Eli Lilly's revenue jumped 48% year over year to $23 billion, while adjusted earnings per share rose 33% year over year to $8.38.
Sales from Eli Lilly's Mounjaro, a diabetes medicine, soared 91% year over year to $9.9 billion, while sales of Zepbound, approved for weight loss and obstructive sleep apnea, grew 46% to $4.9 billion. Can anything stop Eli Lilly's momentum? Here's one thing that might do so.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly generates most of its revenue from Mounjaro and Zepbound, which have the same active ingredient, tirzepatide, a medicine that mimics the action of the GLP-1 and GIP gut hormones. In the second quarter, sales from these two medicines accounted for almost 65% of the company's top line. Eli Lilly also markets Foundayo, an oral GLP-1 approved for weight loss, although it was approved in April and doesn't yet contribute much to its financial results.
Still, the point is that Eli Lilly's lineup is concentrated at the top, with just a couple of brands responsible for most of the recent momentum. Other pharmaceutical giants are well aware of Eli Lilly's GLP-1 success, and they are seeking to launch competing therapies.
#lilly #sales #loss #billion
Sales from Eli Lilly's Mounjaro, a diabetes medicine, soared 91% year over year to $9.9 billion, while sales of Zepbound, approved for weight loss and obstructive sleep apnea, grew 46% to $4.9 billion. Can anything stop Eli Lilly's momentum? Here's one thing that might do so.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly generates most of its revenue from Mounjaro and Zepbound, which have the same active ingredient, tirzepatide, a medicine that mimics the action of the GLP-1 and GIP gut hormones. In the second quarter, sales from these two medicines accounted for almost 65% of the company's top line. Eli Lilly also markets Foundayo, an oral GLP-1 approved for weight loss, although it was approved in April and doesn't yet contribute much to its financial results.
Still, the point is that Eli Lilly's lineup is concentrated at the top, with just a couple of brands responsible for most of the recent momentum. Other pharmaceutical giants are well aware of Eli Lilly's GLP-1 success, and they are seeking to launch competing therapies.
#lilly #sales #loss #billion
26 days ago
As of 11:38 AM ET, the S&P 500 (SNPINDEX:^GSPC) is down 0.44% to 7,623, the Nasdaq Composite (NASDAQINDEX:^IXIC) has fallen 0.44% to 26,217 as cooling artificial intelligence sentiment weighs on growth stocks, and the Dow Jones Industrial Average (DJINDICES:^DJI) is trading 0.36% lower to 52,422.
Gold is down 1.88% to $4,325.10, and the 10-Year Treasury yield has slipped 0.02% to 4.96%, after reaching 5% for the first time since 2023. Communication stocks and healthcare are leading sector gains, while basic materials and industrials are underperforming.
Meta Platforms is climbing today after Goldman Sachs maintained a Buy rating, stressing the potential upside from its Muse AI agent. Micron Technology tumbled over 5% following warnings about the risks of rapid AI development. Those same concerns drove gains in cybersecurity stocks -- CrowdStrike Holdings soared 15%.
Tech leaders have issued dire warnings about the risks of rapid artificial intelligence (AI) development in recent days, prompting an industrywide pullback. Anthropic CEO Dario Amodei and OpenAI CEO Sam Altman both highlighted the dangers that advanced systems could quickly move beyond human control and called for a slower pace of development.
Investors fear any slowdown could impact demand for AI infrastructure, pressuring some of this year's outperformers, such as Marvell Technology, CoreWeave, and Intel. Those worries are understandable, but it is important think about how any controls on AI development might impact long-term growth. Near-term sentiment may slip, but AI isn't going to disappear, and there is a chance that a slower build-out could actually strengthen the industry in the long term.
#down
Gold is down 1.88% to $4,325.10, and the 10-Year Treasury yield has slipped 0.02% to 4.96%, after reaching 5% for the first time since 2023. Communication stocks and healthcare are leading sector gains, while basic materials and industrials are underperforming.
Meta Platforms is climbing today after Goldman Sachs maintained a Buy rating, stressing the potential upside from its Muse AI agent. Micron Technology tumbled over 5% following warnings about the risks of rapid AI development. Those same concerns drove gains in cybersecurity stocks -- CrowdStrike Holdings soared 15%.
Tech leaders have issued dire warnings about the risks of rapid artificial intelligence (AI) development in recent days, prompting an industrywide pullback. Anthropic CEO Dario Amodei and OpenAI CEO Sam Altman both highlighted the dangers that advanced systems could quickly move beyond human control and called for a slower pace of development.
Investors fear any slowdown could impact demand for AI infrastructure, pressuring some of this year's outperformers, such as Marvell Technology, CoreWeave, and Intel. Those worries are understandable, but it is important think about how any controls on AI development might impact long-term growth. Near-term sentiment may slip, but AI isn't going to disappear, and there is a chance that a slower build-out could actually strengthen the industry in the long term.
#down
1 month ago
Nearly all the major crypto-linked stocks surged on Sep. 3 following the rebound in the crypto market.
The Coinbase Global (Nasdaq: COIN) stock surged more than 10% to trade above $193. The largest crypto trading exchange in the United States, Coinbase launched derivative contracts in Canada on Sep. 2.
Related: Coinbase taps Musk ally to board of directors
The Circle Internet Group (NYSE: CRCL) stock also surged more than 15% to trade above $102 today. The crypto giant, well-known for the USDC stablecoin, last week announced a partnership deal with Chelsea FC.
The shares of Strategy (Nasdaq: MSTR), formerly MicroStrategy, rallied nearly 15% to trade above $141. The company disclosed earlier this week that it finally bought Bitcoin after two months.
#Coinbase
The Coinbase Global (Nasdaq: COIN) stock surged more than 10% to trade above $193. The largest crypto trading exchange in the United States, Coinbase launched derivative contracts in Canada on Sep. 2.
Related: Coinbase taps Musk ally to board of directors
The Circle Internet Group (NYSE: CRCL) stock also surged more than 15% to trade above $102 today. The crypto giant, well-known for the USDC stablecoin, last week announced a partnership deal with Chelsea FC.
The shares of Strategy (Nasdaq: MSTR), formerly MicroStrategy, rallied nearly 15% to trade above $141. The company disclosed earlier this week that it finally bought Bitcoin after two months.
#Coinbase
1 month ago
Billionaire Stanley Druckenmiller made two very different-looking AI purchases in the second quarter that share one underlying thesis. Duquesne Family Office increased its Amazon.com, Inc. (NASDAQ:AMZN) position by 1,083% to 541,600 shares and opened a 72,900-share stake in Advanced Micro Devices, Inc. (NASDAQ:AMD). One company rents computing capacity through AWS; the other supplies accelerators and server processors. Together, the positions give Duquesne exposure to an AI infrastructure platform and a credible alternative chip supplier, although the filing does not disclose Druckenmiller's rationale.
Amazon.com, Inc. (NASDAQ:AMZN) offers the demand platform. AWS revenue grew 36.7% in the second quarter, while Amazon's capital-spending trajectory approached roughly $220 billion. The bull case is that its cloud customer relationships, custom silicon, and enormous infrastructure base let it capture AI usage across models and chips. The bear case is that depreciation, power, and construction costs arrive before utilization. Even strong cloud growth must eventually produce returns on a spending program larger than many national economies.
Advanced Micro Devices, Inc. (NASDAQ:AMD) offers more direct operating leverage. Its data-center revenue more than doubled, and customers want an alternative to Nvidia for accelerators and CPUs. If AMD's software improves and hyperscalers deploy Instinct at scale, revenue can grow faster than the broader infrastructure market. Yet it must compete against an entrenched platform while also funding an aggressive roadmap. A second-source narrative is valuable, but only sustained deployments turn it into durable margins.
The common exposure works because Amazon can profit from rising AI consumption regardless of which merchant chip gains share, while AMD can benefit if that consumption creates room for multiple suppliers. The risks also interact. Amazon's own chips could limit AMD's opportunity, and slower cloud utilization would pressure both the buyer of infrastructure and the seller of processors. Both positions could benefit if the market grows faster than those internal conflicts.
Hedge funds moved in the same direction. Amazon ownership rose to 369 funds in the second quarter from 353, while AMD ownership jumped to 164 from 134. Arrowstreet Capital increased its Amazon position 24% to 40.3 million shares, and Marshall Wace raised its AMD common-share stake 3% to 3.9 million shares. As of August 14, 40.1 million AMD shares were sold short, equal to 2.47% of the float and 1.5 days of trading volume. The modest short-interest snapshot shows limited reported short positioning in AMD; it does not resolve whether AMD can capture enough of the spending Amazon is helping unleash.
#amazon #shares
Amazon.com, Inc. (NASDAQ:AMZN) offers the demand platform. AWS revenue grew 36.7% in the second quarter, while Amazon's capital-spending trajectory approached roughly $220 billion. The bull case is that its cloud customer relationships, custom silicon, and enormous infrastructure base let it capture AI usage across models and chips. The bear case is that depreciation, power, and construction costs arrive before utilization. Even strong cloud growth must eventually produce returns on a spending program larger than many national economies.
Advanced Micro Devices, Inc. (NASDAQ:AMD) offers more direct operating leverage. Its data-center revenue more than doubled, and customers want an alternative to Nvidia for accelerators and CPUs. If AMD's software improves and hyperscalers deploy Instinct at scale, revenue can grow faster than the broader infrastructure market. Yet it must compete against an entrenched platform while also funding an aggressive roadmap. A second-source narrative is valuable, but only sustained deployments turn it into durable margins.
The common exposure works because Amazon can profit from rising AI consumption regardless of which merchant chip gains share, while AMD can benefit if that consumption creates room for multiple suppliers. The risks also interact. Amazon's own chips could limit AMD's opportunity, and slower cloud utilization would pressure both the buyer of infrastructure and the seller of processors. Both positions could benefit if the market grows faster than those internal conflicts.
Hedge funds moved in the same direction. Amazon ownership rose to 369 funds in the second quarter from 353, while AMD ownership jumped to 164 from 134. Arrowstreet Capital increased its Amazon position 24% to 40.3 million shares, and Marshall Wace raised its AMD common-share stake 3% to 3.9 million shares. As of August 14, 40.1 million AMD shares were sold short, equal to 2.47% of the float and 1.5 days of trading volume. The modest short-interest snapshot shows limited reported short positioning in AMD; it does not resolve whether AMD can capture enough of the spending Amazon is helping unleash.
#amazon #shares
